Summary: MicroRNAs (miRNAs) post-transcriptionally regulate mRNA expression, controlling global cell function. Altered expression or function of miRNAs causes various diseases. Chemically induced changes in miRNA expression in human tissues are not fully understood. We investigated the changes in miRNA expression by rifampicin, which modulates the expression of various genes related to drug metabolism and pharmacokinetics, in human hepatocytes, and evaluated the relationship with the gene expression changes. We found that 23 miRNAs were increased (>2-fold) and 17 miRNAs were decreased (<0.5-fold) among 150 detected miRNAs, whereas 60 genes were increased and 105 genes were decreased among 22,673 detected genes upon treatment with 10 µM rifampicin. Changes in 17 intragenic miRNAs out of 40 altered miRNAs did not occur in parallel with alterations in their host genes. We searched for the target mRNAs of the miRNAs altered by rifampicin and found that the changes in expression of 16 mRNA/miRNA pairs were inversely associated. Thus, some mRNA expression altered by rifampicin may result from miRNA regulation. In conclusion, we found that rifampicin altered miRNA expression in human hepatocytes. We obtained new insight on the mechanism of the miRNA expression changes and the complicated relationship with gene transcripts.
Introduction
MicroRNAs (miRNAs), a class of non-coding RNAs of 20-22 nucleotides in length, regulate gene expression through translational repression or mRNA degradation by partial base pairing with target mRNAs. In mammals, most miRNA genes, like mRNAs, are transcribed by RNA polymerase II.
1) The long transcripts, called primary miRNAs (pri-miRNAs), are processed by Drosha and a cofactor, DiGeorge syndrome critical region gene 8 (DGCR8), into 60-100 nucleotide hairpin-shaped precursor miRNAs (premiRNAs). The pre-miRNAs are then exported into the cytoplasm and are cleaved near the terminal loop by Dicer and a cofactor TAR RNA-binding protein 2 (TRBP). The double-strand small RNAs are loaded into Argonaute 2 (AGO2) protein and unwound into single-stranded mature miRNAs, which can bind to target mRNAs.
More than 2,000 mature human miRNAs are registered in the miRBase database (http://www.mirbase.org/). The genes encoding miRNAs are dispersed throughout the genome in intragenic (intronic and exonic) or intergenic regions. In human, miRNAs are variably distributed in intronic (42.6%), exonic (5.3%), and intergenic regions (52.1%).
2) It has been recognized that intergenic miRNAs are transcribed through their own promoters, whereas intragenic miRNAs are co-transcribed with their host genes through a common promoter.
3) Recent findings revealed that, in addition to transcriptional regulation, post-transcriptional regulation is also involved in miRNA expression, that is, modulation of processing as follows: SMAD binds to Drosha to promote cleavage of pri-miR-21 to pre-miR-21, 4) and Lin-28 inhibits cleavage of pre-let-7 to mature let-7.
5) Furthermore, new pathways for miRNA biogenesis were recently reported: the "mirtrons" pathway, where a subset of miRNAs are derived from short hairpin introns that bypass cleavage by Drosha or the "simtrons" pathway, a biogenesis of splicing-independent mirtron-like miRNAs that requires Drosha but not the other canonical miRNA biogenesis components. 6) These recent findings suggest that the regulation of miRNA expression is more complicated than expected.
Previous studies reported that miRNA expression is altered by exposure to carcinogens, toxins, drugs and hormones. We have an interest in miRNA expression changes from exposure to Wy-14,643, estradiol, GW4064, and dexamethasone, ligands of peroxisome proliferator-activated receptor ¡, 7) estrogen receptor ¡, 8) farnesoid X receptor, 9) and glucocorticoid receptor, 10) respectively. We speculate that altered expression of miRNAs is caused by transactivation of these nuclear receptors. In addition, estrogen receptor ¡ potentially alters the processing of miRNAs via an interaction with Dead box helicases p68 and p72, which form a complex with Drosha.
11) Thus, the activation of nuclear receptors could affect the expression of not only mRNAs but also miRNAs. In the present study, we were particularly interested in the pregnane X receptor (PXR). This receptor is a key regulator of drug metabolism and elimination and bile acid homeostasis 12) through the transactivation of many drug-metabolizing enzymes and drug transporters by a broad spectrum of exogenous and endogenous compounds such as drugs, herbs, pesticides, environmental contaminants, steroids and bile acids. We sought to characterize miRNA expression changes caused by PXR activation in human hepatocytes and examine the relationship with gene expression changes.
Methods
Chemicals and reagents: Rifampicin was purchased from Sigma-Aldrich (St. Louis, MO). RNAiso and nuclease-free water were purchased from Takara (Shiga, Japan) and Ambion (Austin, TX), respectively. Megaplex RT Human Pool A, Megaplex PreAmp Primers Human Pool A, TaqMan PreAmp Master Mix, TaqMan Universal Master Mix (No AmpErase UNG), and TaqMan Human MicroRNA Array A Card v2.0 were purchased from Life Technologies (Carlsbad, CA). All other reagents were of the highest grade commercially available.
Cell culture: Human cryopreserved hepatocytes (lot no. CHA, a pooled sample from 10 donors, Supplemental Table 1 , Celsis, Baltimore, MD) were seeded into 6-well plates at 1 © 10 6 cells/well and maintained in hepatocyte culture medium (HCM) (Lonza, Basel, Switzerland) at 37°C under 5% CO 2 . After 3 h, the culture medium was changed to HCM not containing BSA-FAF (bovine serum albumin-fatty acid free), epidermal growth factor or antibiotics and then treated with 10 µM rifampicin or 0.1% DMSO as a control. The hepatocytes were maintained for 48 h until harvest.
RNA extraction: Total RNA was isolated from human hepatocytes using RNAiso (Takara) and then purified using a miRNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. The purity and quantity of RNA were assessed using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE).
TaqMan microRNA arrays: The expression profiles of miRNAs were assessed using a TaqMan Human MicroRNA Array A Card v2.0 (Life Technologies) containing 377 miRNA probes. All of the procedures were performed following the manufacturer's instructions. Briefly, total RNA (130 ng) was reverse transcribed using Megaplex RT Primer Pool A and a Taqman MicroRNA Reverse Transcription Kit. Pre-amplification was carried out using Megaplex PreAmp primers and TaqMan PreAmp Master Mix. miRNA expression was determined by quantitative real-time PCR using a TaqMan Human MicroRNA Array with the 7900HT Fast Real-Time PCR System (Life Technologies) following the manufacturer's recommended cycling conditions. Cycle threshold (Ct) values were calculated using SDS software v.2.3 with a baseline of 3-15 and assigned a minimum threshold of 0.2. The miRNAs with Ct values over 35 in both the rifampicin-and vehicle-treated groups were excluded from the data analysis because non-specific amplification was surmised. The Ct value of MammU6, an endogenous control gene, was used for normalization. The expression levels were represented by "Ct values, and fold changes were determined by the ""Ct method.
TaqMan microRNA assays: The expression level of miR-16, miR-31, miR-34a, miR-133a, and U6 snRNA were determined by quantitative real-time PCR using TaqMan MicroRNA Assays (Life Technologies). All procedures were performed following the manufacturer's instructions. The cDNAs were synthesized using a TaqMan MicroRNA Reverse Transcription Kit and RT primer according to the manufacturer's protocol. TaqMan Universal PCR Master Mix (No AmpErase UNG) and TaqMan MicroRNA Assay were added to the cDNA sample, and the real-time PCR was performed using MP3000P (Stratagene, La Jolla, CA) with MxPro QPCR software. miRNA levels were normalized with U6 snRNA, and fold changes between the two samples were determined by the ""Ct method.
DNA microarray: DNA microarray analysis was performed by Hokkaido System Science (Sapporo, Japan). cRNA used for the DNA microarray hybridization was prepared according to the OneColor microarray-based gene expression analysis protocol (Agilent Technologies). Briefly, a T7 sequence was introduced as total RNA samples (200 ng) of each rifampicin-and vehicle-treated group were reverse-transcribed into cDNA. T7 RNA polymerase-driven RNA synthesis was used for RNA preparation and labeling with Cy3 dye. Cyanine-labeled cRNA was purified using the RNeasy Mini Kit (Qiagen) and then hybridized to an Agilent 44K human oligonucleotide microarray (Agilent Technologies) at 65°C overnight. The arrays were washed according to the manufacturer's specifications and scanned using an Agilent Technologies Microarray Scanner. Feature extraction software provided by Agilent was used to quantify the intensity of fluorescent images and to normalize results by subtracting local background fluorescence, according to the manufacturer's instructions. The expression level of each gene was analyzed by GeneSpring software (Agilent Technologies). Briefly, after the processed data were imported into the software, they were normalized based on the default normalizing settings for one-color experiments. To filter out noise, we selected genes with the following criteria: glsSaturated = 0, glsFeatNonUnifOL = 0, glsBGNonUnifOL = 0, glsFeatPopnOL = 0, glsBGPopnOL = 0, glsPosAndSignif = 1, and glsWellAboveBG = 1. A threshold of 2-fold change in gene expression was used as the cutoff value.
Real-time RT-PCR for CYP3A4, CYP2B6, and MDR1: The cDNAs were synthesized from total RNA using ReverTraAce (Toyobo, Osaka, Japan). CYP3A4 13) and MDR1 14) mRNAs were determined by real-time RT-PCR, as described previously. The forward and reverse primers for CYP2B6 were 5A-CAAGGACC-TCATCGACACC-3A and 5A-AATCACCTGTTCAATCTCCC-3A, respectively. A 1-µl portion of the reverse-transcribed mixture was added to a PCR mixture containing 8 pmol of each primer, 10 µl of SYBR Premix Ex Taq solution and 0.25 µl ROX in a final volume of 20 µl. The PCR conditions were as follows: after an initial denaturation at 95°C for 30 s, the amplification was performed by denaturation at 94°C for 6 s, annealing and extension at 62°C for 20 s for 40 cycles. The real-time RT-PCR was performed using Mx3000P (Stratagene, La Jolla, CA) with the MxPro QPCR software. The mRNA levels were normalized with GAPDH mRNA determined by real-time RT-PCR, as described previously.
15)
Statistical analysis: Comparison of two groups was made with an unpaired, two-tailed Student's t test. A value of p < 0.05 was considered statistically significant.
Results
Effects of rifampicin treatment on miRNA expression in human hepatocytes: miRNA expression levels in human hepatocytes treated with 10 µM rifampicin or vehicle (DMSO) were determined by TaqMan MicroRNA Array. The numbers of miRNAs with a Ct < 35 in rifampicin-and vehicle-treated groups were 164 and 153, respectively. Among those, 150 miRNAs with Ct values below 35 in both groups were subsequently analyzed. The expression levels of the 150 miRNA in rifampicin-and vehicle-treated groups, sorted from higher to lower level in the vehicle-treated group, are depicted in Figure 1 . miR-122 was the most abundant miRNA in human hepatocytes, which supported a previous report in the human liver, 16) and was followed by miR-191, miR-146b-5p and miR-29a.
We then sought to identify the miRNAs with expression changes induced by rifampicin treatment and found that 23 miRNAs were increased >2-fold and 17 were decreased <0.5-fold (Fig. 1) . These miRNAs are listed in Table 1 in order of highest fold difference. Among the 23 increased miRNAs, miR-145 (52-fold) and miR-143 (19-fold) showed relatively large changes, whereas the remaining 21 miRNAs showed moderate changes (8 to 2 fold). Among the 17 decreased miRNAs, miR-362-3p changed dramatically (500-fold), miR-218, miR-148b, miR-133a, miR-874, and miR-29a showed relatively large changes (100 to 11-fold), and 11 miRNAs showed moderate changes (9 to 2-fold). To validate the changes in miRNA expression determined by TaqMan MicroRNA array analysis, we performed TaqMan MicroRNA assays for some miRNAs. The significantly up-regulated miRNAs, miR-145 and miR-143, were not detected by TaqMan MicroRNA assays (data not shown), probably because a preamplification step which is included in detection by TaqMan microRNA array is excluded TaqMan MicroRNA assays. However, in the case of four randomly selected miRNAs, it was confirmed that the miRNA expression fold changes were reproducible (Fig. 2) .
It has been reported that multiple clustered miRNAs are often coordinately expressed because they are produced from a single polycistronic unit. 17) When we investigated the basal expression level of miRNAs in the miR-17-92 cluster, we noticed that the Ct values of miR-17, miR-18a, miR-19a and miR-20a (20.42, 31.41, 26.69, and 23.09, respectively) were highly variable. Similarly, the Ct values of let-7e, miR-99b, and miR-125a (25.39, 33.72, and 29.41, respectively) in the let-7e cluster were variable. Thus, transcriptional regulation could not be the sole factor determining the basal expression of mature miRNAs. However, the miR-145 and miR-143 cluster was coordinately up-regulated by rifampicin treatment, and the miR-362-3p and miR-532-3p cluster was coordinately down-regulated by rifampicin treatment. These observations led to the hypothesis that these polycistronic miRNAs might be commonly regulated, although the extent of the changes varied. Although miR-200a was up-regulated (7-fold), the other members of the same cluster, miR-200b and miR-429, were not significantly changed (1.49-and 1.61-fold). Collectively, it seems that mechanisms other than transcriptional regulation contribute largely to the basal and altered expression of miRNAs.
Effects of rifampicin treatment on gene transcript expression in human hepatocytes: We characterized rifampicininduced changes in gene transcript expression in human hepatocytes. The expression of 22,673 genes out of 44,000 genes on the array was detected. We found that 60 gene transcripts were increased over 2-fold ( Table 2) . Among those transcripts, CYP3A7 (4.7-fold), CYP3A4 (4.3-fold), CYP3A5 (2.9-fold), CYP2B6 (2.7-fold), CYP2C19 (2.2-fold), CYP2C9 (2.1-fold), and MDR1 (1.2 fold) were known to be induced by rifampicin. Unexpectedly, a large number of gene transcripts (105) were decreased (<0.5-fold) by rifampicin treatment ( Table 2) . Notably, the transcripts of RNF6 (ring finger protein 6, an ubiquitin ligase), MYH16 (sarcomeric myosin heavy chain), and CLK2 (CDC-like kinase 2) were decreased. Nearly half of the decreased genes (45 out of 105) were unassigned genes, such as A_33_P#######, or genes with unknown function, such as ENST#######, LOC#########, and ZNF### (which have been classified as members of the zinc finger protein family). To validate the changes in gene transcript expression determined by DNA microarray analysis, we performed real-time RT-PCR for some selected genes. As shown in Figure 3 , the changes in CYP3A4, CYP2B6, and MDR1 mRNAs were reproducible. We subsequently investigated the relationship between rifampicin-induced expression changes in gene transcripts and miRNAs.
Relationship between expression changes in intragenic miRNAs and their host gene transcripts: It has been reported that intragenic miRNAs and their host gene transcripts are cotranscribed from a common promoter.
3) We investigated whether rifampicin-induced expression changes in intragenic miRNAs and their host gene transcripts were synchronized. Among the 40 miRNAs with rifampicin-induced expression changes, 17 are intragenic miRNAs (marked by a gray color in Table 1 ). Rifampicin-induced miRNA and host gene expression changes are listed in Table 3 . Most cases showed a one-to-one correspondence between the miRNA and host gene, but miR-218 genes are on two loci, chromosomes 4 and 11 encoding SLIT2/miR-218-1 and SLIT3/miR-218-2, respectively. For such miRNAs, we need additional experiments to determine which locus predominantly produces the mature miRNA. Aside from basal expression, the fold changes in miR-218 and its host genes were dissimilar. The CLCN5 gene includes two genes for miR-532-3p and miR-628-5p. These miRNAs were decreased by rifampicin treatment, but the host gene was not. The changes in miRNA and host gene expression were inconsistent, even in the one-to-one correspondence pairs. For example, rifampicin treatment induced a 5.82-fold increase in miR-26b, whereas the host gene transcript CTDSP1 hardly changed (1.05-fold). Rifampicin induced a 0.02-fold decrease in miR-148b, whereas the host gene transcript COPZ1 was unchanged (1.06-fold). Although we found one rare case of coordinated changes in miRNA and host gene transcript (miR-31 and LOC554202), the present study revealed that changes in most intragenic miRNAs were not necessarily accompanied by changes in their host gene transcripts.
Conversely, we investigated whether rifampicin-induced changes in host gene transcript expression were accompanied by expression changes in their corresponding miRNAs. Among the gene transcripts shown in Table 2 , only 3 genes, encoding FOXP1, PDE4D and KIRREL3, include a miRNA gene (miR-1284, miR-582 and miR-3167, respectively) in their intron. Unfortunately, we could not determine the expression level or fold change in The log 2 expression is represented as Ct value and normalized to MammU6. Fold change in miRNA expression is colored red or green to represent more than 2-fold increase or less than 0.5-fold decrease, respectively. miRNAs are lined up in descending order of expression in DMSO-treated sample. Data are from a single determination using pooled human hepatocytes from 10 donors. (For interpretation of the reference to color in this figure legend, the reader is referred to the web version of this article.) miR-1284 and miR-3167 expression because the TaqMan Micro-RNA Array card we used did not include probes for these miRNAs. miR-582 expression in human hepatocytes was too low to be detected. Thus, the analysis was inconclusive.
Prediction of target genes of miRNAs with expression changes induced by rifampicin treatment: miRNAs silence genes through translational repression or mRNA degradation, but it has become apparent that many cases are accompanied by a decrease in mRNA levels. 18, 19) We sought to find the miRNA/target gene pairs with inversely associated expression changes induced by rifampicin treatment. We used well-known prediction programs including TargetScan v6.2 (http://www.targetscan.org/), micro-RNA.org (http://www.pictar.org/), or PITA (http://genie.weizmann. ac.il/) to find potential target genes of miRNAs listed in Table 1 . An enormous number of target genes has been predicted, and the target gene list was compared with the gene transcripts in Table 2 . Among them, we identified 16 miRNA/target gene pairs with inversely associated expression changes ( Table 4) . For examples, miR-143 and miR-26b were up-regulated by rifampicin treatment while the predicted targets of miR-143 and miR-26b, RNF6, were down-regulated by rifampicin treatment. Let-7a was downregulated by rifampicin treatment while the predicted target of let7a, ACTR10, was up-regulated by rifampicin treatment. FOXP1 had been reported to be a target of miR-34a based on a finding that the overexpression of miR-34a resulted in the decrease of FOXP1 mRNA expression in human pre-B cell-derived NALM6 cells. 20) Although further studies are needed to validate whether these gene transcripts are actually the targets of the miRNAs in human hepatocytes, we identified some examples of inversely associated changes in miRNA and target transcript expression following rifampicin treatment. The results may imply that the miRNA expression changes are an additional underlying mechanism of gene expression changes by rifampicin other than the transactivation via PXR.
Discussion
In this study, we investigated rifampicin-induced miRNA expression changes in human hepatocytes and found that 23 miRNAs were increased (>2-fold) and 17 miRNAs were decreased (<0.5-fold) out of 150 detected miRNAs. The largest changes, 52-fold increase and 500-fold decrease, were unexpected because previous studies have reported modest alterations in miRNA expression by ligands of some transcriptional factors: 7-fold by estradiol in human endometrium cells, 8) 3-fold by androgen in CaP cells, 21 ) and 1.4-fold by benzo(a)pyrene in mice. 22) Changes in miRNA expression could occur at the transcriptional level because rifampicin is a typical ligand of PXR. However, based on the analyzed results of basal expression and changes in multiple clustered miRNA expression, it is possible that post-transcriptional regulation or modulated processing of miRNAs contributes largely to miRNA expression.
We performed DNA microarray analysis to characterize rifampicin-induced changes in gene transcript expression. We found that 165 gene transcripts out of 22,673 detected genes were altered by rifampicin treatment in human hepatocytes. The maximum change unexpectedly peaked at 5-fold, which was smaller than miRNA expression changes. Measurement platform differences, hybridization array versus TaqMan real-time PCR, might be one reason for this unexpected result. Another intriguing observation is that the percent changed/not changed by rifampicin was considerably higher in miRNAs (40/150: 27%) than in gene transcripts (165/22,673: 0.7%). Although the above caveat may affect this observation as well, the required processing during miRNA production needed to produce mature transcripts may be another reason for this difference, which is discussed later. The upregulation of 60 gene transcripts could be attributed to transactivation of PXR. A larger number of gene transcripts (105 genes) was unexpectedly decreased by rifampicin treatment. These are likely explanations for the down-regulation: 1) PXR might upregulate some transcriptional repressors, 2) PXR might repress The miRNAs shaded in gray are intragenic miRNAs. These miRNAs are located in a cluster on chromosome X.
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transcription without binding to the promoter, as reported for the CYP7A1 gene, 23) or 3) PXR might disrupt an active chromatin structure to repress transcription, as reported for the SULT1E1 gene. 24) These down-regulation mechanisms might also be involved in the down-regulation of miRNAs by rifampicin.
Approximately half of human miRNAs are intragenic miRNAs.
2) It is believed that intragenic miRNAs are co-transcribed with their host gene through a common promoter. We investigated whether rifampicin-induced expression changes in intragenic mature miRNAs coincided with changes in miRNA gene transcription. We found that changes in most intragenic miRNAs did not necessarily mirror changes in their host gene transcripts. There is accumulating evidence for post-transcriptional regulation of miRNA expression that supports our finding. p68/p72, 25) SMAD 4) and p53 26) bind to Drosha to promote the processing of primiRNAs. Estrogen receptor ¡ binds to p68/p72 to inhibit the processing of pri-miRNAs.
11) Lin-28 5) and KSRP 27) bind to the stem loop of the pre-miRNA to modulate the function of Dicer. The results of this study imply that rifampicin-activated PXR potentially affects miRNA processing. In addition, it is possible The gene transcripts shaded in gray are miRNA host genes.
that rifampicin itself directly affects miRNA processing, as enoxacin binds to TRBP to enhance miRNA processing, 28) or rifampicin might alter the expression of some factors involved in miRNA processing. The hypothesis was supported by a finding that the pri-miR-29a level was not changed by rifampicin treatment (data not shown), although the mature miR-29a was significantly decreased. Further studies are needed to understand the mechanisms behind rifampicin-dependent post-transcriptional modification of miRNA expression. To determine whether the observed rifampicin-induced miRNA and gene expression changes are mediated by PXR or not, the PXR knockdown experiment would be useful.
Finally, we sought to examine whether rifampicin-induced changes in miRNA and target gene transcript expression were inversely associated. Based on the target genes predicted by in silico analysis, we could find inversely associated miRNA/target gene pairs ( Table 4 ), implying that the miRNA expression changes might be an additional underlying mechanism of gene expression changes by rifampicin other than the transactivation via PXR. However, there were miRNA/validated target gene pairs that were exceptions. miR-199a-3p, which was up-regulated by rifampicin, has been reported to regulate CD44. 29) miR-218 and miR-296-5p, which were down-regulated by rifampicin, have been reported to regulate Onecut 30) and PUMA, 31) respectively, in human liverderived cell lines. In this study, the expression of these target gene transcripts was not altered by rifampicin treatment (data not shown). Thus, the changes in miRNA expressions were not necessarily correlated with changes in target gene transcript expression, which supported a previous report. 32) This result is not surprising because miRNA can decrease protein level without affecting mRNA level. Proteomic analysis would aid examination of changes in protein expression and effects of miRNA expression changes on target genes.
During the preparation of this manuscript, Ramamoorthy et al. 33) reported similar changes in miRNA expression in human hepatocytes by rifampicin. In their study, human hepatocytes from seven subjects were treated with 10 µM rifampicin for 24 h, and the expression of miRNA and 40 kinds of P450 mRNAs was measured by TaqMan OpenArray Human MicroRNA Panel and RNA-seq, respectively. When they used a p value cutoff of 0.05, they observed 33 up-regulated and 30 down-regulated miRNAs. In comparison with our study, the changes in a few miRNAs, such as miR-26b and miR-21 (up-regulated), miR-149 and miR-532-3p (down-regulated), were common. The difference in the changed miRNAs by rifampicin between the two studies might be due to mainly the differences in the platforms of array analysis and data analysis (cutoff and normalization, although they did not state it clearly) and partly the differences in exposure time of rifampicin and lots of hepatocytes. The authors based their discussion on the correlation analyses between the changes in miRNA and P450 expressions, whereas we analyzed the relationship with host genes or predicted target mRNAs of the changed miRNAs based on comprehensive analysis of gene transcript expression by DNA microarray analysis.
In conclusion, we found that rifampicin treatment substantially changed miRNA expression in human hepatocytes. Using gene transcript expression analysis, we obtained new insight on the mechanism behind miRNA expression changes and the complicated relationship between miRNA and gene transcripts. The clinical significance of rifampicin-induced miRNA expression changes is worthy of future studies.
